Literature DB >> 34249532

Prevalence of Vitamin D Inadequacy in Urolithiasis Patients.

Kunal Dholakia1, Nivash Selvaraj2, Narasimhan Ragavan1.   

Abstract

Introduction The role of vitamin D in kidney stone disease is unclear. Current evidence and existing studies are inconsistent and inconclusive. The objective of this study is to assess the prevalence of vitamin D (VD) inadequacy (VDI) and metabolic abnormalities in urolithiasis patients presenting to a tertiary care center. Materials and methods This is a prospective case-control study of 200 patients divided into two groups - Group 1: 100 urolithiasis patients (case group), and Group 2: 100 non-urolithiasis patients (control group) - which was conducted from January 2016 to January 2017. Demographic, clinical data, parathyroid level, serum 25-hydroxy VD [25(OH)D], and metabolic stone work-up were recorded and analyzed.  Results Patient demographics were comparable in both groups. The prevalence of vitamin D inadequacy in urolithiasis patients was 95% as compared to 57% in the control group. The mean value ± SD of serum vitamin D in urolithiasis patients (16.5 ± 8.6 ng/mL) was significantly lower than in non-urolithiasis patients (28.7 ± 8.3 ng/mL) (p = <0.0001). Thirty-seven percent of the patients were recurrent stone formers. Hyperparathyroidism was observed in 77% of the patients and 71% of them were secondary to VDI. Conclusion Urolithiasis patients were found to have an increased prevalence of deficient VD related to secondary hyperparathyroidism.
Copyright © 2021, Dholakia et al.

Entities:  

Keywords:  inadequacy; parathyroid level; prevalence; urolithiasis; vitamin d

Year:  2021        PMID: 34249532      PMCID: PMC8249211          DOI: 10.7759/cureus.15379

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  30 in total

Review 1.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

2.  Evidence for a phosphorus-depletion syndrome in man.

Authors:  M Lotz; E Zisman; F C Bartter
Journal:  N Engl J Med       Date:  1968-02-22       Impact factor: 91.245

3.  Prevalence and metabolic abnormalities of vitamin D-inadequate patients presenting with urolithiasis to a tertiary stone clinic.

Authors:  Mohamed A Elkoushy; Ramsey Sabbagh; Bernard Unikowsky; Sero Andonian
Journal:  Urology       Date:  2011-10-27       Impact factor: 2.649

4.  Normocalcemic hyperparathyroidism in patients with recurrent kidney stones: a disease entity or vitamin D deficiency?

Authors:  Chrysoula Pipili; Nigar Sekecioglu; Dimitrios G Oreopoulos
Journal:  Clin Nephrol       Date:  2012-05       Impact factor: 0.975

Review 5.  Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.

Authors:  John Cunningham; Francesco Locatelli; Mariano Rodriguez
Journal:  Clin J Am Soc Nephrol       Date:  2011-03-31       Impact factor: 8.237

6.  An assessment of parathyroid hormone, calcitonin, 1,25 (OH)2 vitamin D3, estradiol and testosterone in men with active calcium stone disease and evaluation of its biochemical risk factors.

Authors:  Nasser Shakhssalim; Kobra Roohi Gilani; Mahmoud Parvin; Peyman Mohammadi Torbati; Amir H Kashi; Mohaddeseh Azadvari; Banafsheh Golestan; Abbas Basiri
Journal:  Urol Res       Date:  2010-05-19

7.  Vitamin D deficiency and renal calcium transport in the rat.

Authors:  M Yamamoto; Y Kawanobe; H Takahashi; E Shimazawa; S Kimura; E Ogata
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

Review 8.  [Is kidney stone a bone disease?].

Authors:  C Stoermann Chopard; P Jaeger
Journal:  Rev Med Suisse       Date:  2009-06-10

9.  Renal calculi associated with incomplete distal renal tubular acidosis.

Authors:  J W Konnak; B A Kogan; K Lau
Journal:  J Urol       Date:  1982-11       Impact factor: 7.450

Review 10.  Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections.

Authors:  Nikos Roussos; Drosos E Karageorgopoulos; George Samonis; Matthew E Falagas
Journal:  Int J Antimicrob Agents       Date:  2009-10-13       Impact factor: 5.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.